CYTK CYTOKINETICS INC

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: biopharmaceutical development and commercialization focused on muscle biology therapeutics for cardiovascular diseases
• • New product launch: MYQORZO approved by FDA in Dec 2025 for symptomatic oHCM, first commercial sales commenced Q1 2026

Risk Factors

• • Cybersecurity risk oversight led by Audit Committee with tech, risk, finance expertise and regular briefings from CISO, CEO, CFO
• • Dependence on Chief Information Security Officer Eric Brown with 10+ years cybersecurity experience for managing critical security operations

Management Discussion & Analysis

• • Revenue $88.1M in 2025, up $69.6M from $18.5M in 2024, driven by license and milestone revenues from Bayer and Sanofi
• • Operating expenses rose sharply: R&D $416.0M (+23% YoY), G&A $284.3M (+32% YoY), reflecting clinical advancement and commercial readiness

Risk Factors

• • New regulatory risk: FDA workforce reductions and government shutdowns may delay NDA approval this quarter, with aficamten PDUFA date extended to Dec 26, 2025
• • Updated clinical risk: discontinuation of COURAGE-ALS Phase 3 trial due to futility signals increased uncertainty in drug efficacy demonstration

What are the latest CYTK SEC filings in 2026?

CYTOKINETICS INC (CYTK) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on February 24, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did CYTK file its most recent 10-K annual report?

CYTOKINETICS INC (CYTK) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view CYTK 10-Q quarterly reports?

CYTOKINETICS INC (CYTK)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every CYTK 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has CYTK filed recently?

CYTOKINETICS INC (CYTK)'s most recent 8-K was filed on February 24, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find CYTK insider trading activity (Form 4)?

SignalX aggregates every CYTK Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does CYTK file with the SEC?

CYTOKINETICS INC (CYTK) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new CYTK filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for CYTOKINETICS INC (CYTK).

What is CYTK's SEC CIK number?

CYTOKINETICS INC (CYTK)'s SEC CIK (Central Index Key) number is 1061983. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1061983 to look up all CYTK filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find CYTK return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from CYTOKINETICS INC (CYTK) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.